MDM2 proto-oncogene | OKDB#: 217 |
Symbols: | MDM2 | Species: | human | ||
Synonyms: | HDMX, LSKB, hdm2, ACTFS | Locus: | 12q15 in Homo sapiens |
For retrieval of Nucleotide and Amino Acid sequences please go to:
OMIM
Entrez Gene
Mammalian Reproductive Genetics Endometrium Database Resource Orthologous Genes UCSC Genome Browser GEO Profiles new! Amazonia (transcriptome data) new! R-L INTERACTIONS MGI |
General Comment |
MDM2 protein has been shown to bind to p53 by forming a tight complex with the p53 gene, the MDM2 oncogene can inhibit p53-mediated transactivation (Momand et al., 1992). Overexpression of the MDM-2 gene in cells increases tumorigenic potential and overcomes the growth-suppressive activity of p53 (Bueso-Ramos et al., 1993). Transcriptional activation of MDM2 oncogene by p53. bFGF and ECM also increase MDM2 expression 3-5 fold. cAMP suppresses p53-induced MDM2 expression (Hosokawa et al., 1998). ARF binds to MDM2 and promotes the rapid degradation of MDM2 (Zhang et al., 1992).
NCBI Summary: This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells. [provided by RefSeq, Jun 2013] |
||||
General function | Cell death/survival, Anti-apoptotic, Oncogenesis, Nucleic acid binding, DNA binding, Transcription factor | ||||
Comment | Analysis of the predicted amino acid composition of the MDM2 product(s) revealed features similar to those that have been shown to be functionally significant in certain DNA binding proteins/transcriptional activators. These include two potential metal binding motifs and a negatively charged domain rich in acidic amino acid residues (Fakharzadeh et al., 1991). MDM-2 gene expression is altered in a significant fraction of human leukemias and MDM-2 may play a significant role in leukemogenesis (Bueso-Ramos et al., 1993). | ||||
Cellular localization | |||||
Comment | candidate123 | ||||
Ovarian function | Follicle atresia | ||||
Comment | MDM2 protein products down-modulate biochemical activities and biological effects of p53. Hosokawa et al.(1998) have established highly steroidogenic human granulosa cell lines expressing the Ha-ras oncogene and a temperature sensitive (ts) mutant of p53 (p53val135) to test the involvement of p53-downstream genes in the modulation of apoptosis in these cells. They found that basic fibroblast growth factor and components of the extracellular matrix can cross-talk with p53/cAMP-generated signals for apoptosis. These signals may, at least in part, be coordinated by the modulation of Mdm2 expression, which precedes the biochemical events characteristic of apoptosis. MDM2-p53 complexes preferentially found in S/G2M phase of cell cycle [(Fuchs et al., 1998)9732264]. | ||||
Expression regulated by | |||||
Comment | |||||
Ovarian localization | Oocyte, Cumulus, Granulosa | ||||
Comment | |||||
Follicle stages | |||||
Comment | |||||
Phenotypes |
PCO (polycystic ovarian syndrome) |
||||
Mutations |
4 mutations
Species: human
Species: mouse
Species: mouse
Species: human
|
||||
Genomic Region | show genomic region | ||||
Phenotypes and GWAS | show phenotypes and GWAS | ||||
Links |
|
created: | Nov. 30, 1999, midnight | by: |
Garnier email:
home page: |
last update: | March 18, 2020, 3:43 p.m. | by: | hsueh email: |
Click here to return to gene search form